TB-500 is a synthetic peptide associated with thymosin beta-4 activity
It is unclear whether these effects are due to radiation, heating, or both
In some embodiments, the otic pharmaceutical formulation comprises between about 55% to about 95% by weight of the triglycerides
The therapies discussed including peptide therapy and stem cell therapy represent emerging investigational approaches and are not approved treatments for Autism Spectrum Disorder
The peptides VEGFR2 activation and collateral pathway recruitment create conditions for regeneration in injury models
However, data on the packaging of these products often contain inaccurate information on their composition, origin, performance, and use, which might mislead consumers